-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Statistics show that last month, more than 80 financing events (including 10 IPOs) were completed in the global biomedical field
.
Among them, 73 financings with a disclosed amount totaled more than US$4.
8 billion
.
According to the analysis, from the perspective of technology, these investments are mainly concentrated in small molecule drugs and cell therapies, both of which have received 16 financing; however, RNA therapy is also enthusiastic, and a total of 7 companies have received capital favor; and In addition to the former, tRNA, circular RNA, siRNA and other fields are still favored by capital
.
It is worth mentioning that, from the perspective of the amount of funds raised, Linktop Bio, which is engaged in the development of small molecule drugs such as cancer, cardiovascular diseases, and infectious diseases, set a November IPO record in the biomedical field, raising US$325 million; developing new vaccines Shamrock Bio, which is a candidate for biological therapy, followed closely with a fund of 1.
87 billion Hong Kong dollars; GreenLight Biosciences, which develops mRNA vaccines and candidate therapies for infectious diseases, ranked third with a fund of US$124 million
.
On the whole, the industry believes that the current global biomedicine is raising a wave of financing
.
It is worth noting that, in this context, domestic biomedical companies have become investors' "sweet pastry"
.
According to incomplete statistics, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
In the second half of the year, the domestic financing wave continued
.
In the near future, a number of innovative pharmaceutical companies have completed financing one after another, most of which amounted to hundreds of millions of dollars
.
For example, on November 15th, JSI Indah announced the completion of the B round of financing
.
The financing was jointly led by Tigermed and Baidu Ventures, followed by Qianhai Beizeng and Jiuyou Capital.
Old shareholders Juming Venture Capital and Yifeng Capital continued to increase in this round
.
It is reported that this round of financing will be mainly used to fully promote the clinical phase 1/2 research of two core products, namely the oral highly selective ERK1/2 kinase inhibitor JSI-1187 independently developed by JSI, and the new generation of high Selective Aurora A kinase inhibitor VIC-1911
.
On November 4, Changyu Pharmaceutical announced that it has completed a $40 million Series C financing and obtained an over-raising
.
According to reports, the funds raised in this round of financing will continue to develop original dual-target molecules based on Changyu Pharmaceutical’s proprietary coupled drug technology platform, including the first product XG005, which will be launched in the United States and China in Phase III and Phase II acute and chronic pain respectively.
(Including tumor pain, bone and joint pain) clinical trials, phase II overseas clinical trials of transdermal product XG004, and the promotion of other pipeline products
.
From the perspective of the industry, behind the continuous entry of capital is actually a manifestation of the continuous rise of China's biomedical industry
.
In recent years, with the support of favorable policies, in the context of the continuous growth of the domestic pharmaceutical market and the increasing acceptance of innovative therapies in the country, local innovative companies are constantly developing innovative drugs and are facing a large scale.
, While paying more and more attention to innovation in the domestic market, it is also continuing to expand the international market
.
Therefore, affected by this in the future, more and more innovative companies will attract the attention of strategic investors
.
And this will also inject more momentum into the pharmaceutical and biological market, thereby better promoting the innovation and high-quality development of the pharmaceutical and biological industry
.
.
Among them, 73 financings with a disclosed amount totaled more than US$4.
8 billion
.
According to the analysis, from the perspective of technology, these investments are mainly concentrated in small molecule drugs and cell therapies, both of which have received 16 financing; however, RNA therapy is also enthusiastic, and a total of 7 companies have received capital favor; and In addition to the former, tRNA, circular RNA, siRNA and other fields are still favored by capital
.
It is worth mentioning that, from the perspective of the amount of funds raised, Linktop Bio, which is engaged in the development of small molecule drugs such as cancer, cardiovascular diseases, and infectious diseases, set a November IPO record in the biomedical field, raising US$325 million; developing new vaccines Shamrock Bio, which is a candidate for biological therapy, followed closely with a fund of 1.
87 billion Hong Kong dollars; GreenLight Biosciences, which develops mRNA vaccines and candidate therapies for infectious diseases, ranked third with a fund of US$124 million
.
On the whole, the industry believes that the current global biomedicine is raising a wave of financing
.
It is worth noting that, in this context, domestic biomedical companies have become investors' "sweet pastry"
.
According to incomplete statistics, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of the year has reached 23, with a total financing amount of over 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan, including Aotai Biological, Zhijiang Biological, Baike Biological and so on
.
In the second half of the year, the domestic financing wave continued
.
In the near future, a number of innovative pharmaceutical companies have completed financing one after another, most of which amounted to hundreds of millions of dollars
.
For example, on November 15th, JSI Indah announced the completion of the B round of financing
.
The financing was jointly led by Tigermed and Baidu Ventures, followed by Qianhai Beizeng and Jiuyou Capital.
Old shareholders Juming Venture Capital and Yifeng Capital continued to increase in this round
.
It is reported that this round of financing will be mainly used to fully promote the clinical phase 1/2 research of two core products, namely the oral highly selective ERK1/2 kinase inhibitor JSI-1187 independently developed by JSI, and the new generation of high Selective Aurora A kinase inhibitor VIC-1911
.
On November 4, Changyu Pharmaceutical announced that it has completed a $40 million Series C financing and obtained an over-raising
.
According to reports, the funds raised in this round of financing will continue to develop original dual-target molecules based on Changyu Pharmaceutical’s proprietary coupled drug technology platform, including the first product XG005, which will be launched in the United States and China in Phase III and Phase II acute and chronic pain respectively.
(Including tumor pain, bone and joint pain) clinical trials, phase II overseas clinical trials of transdermal product XG004, and the promotion of other pipeline products
.
From the perspective of the industry, behind the continuous entry of capital is actually a manifestation of the continuous rise of China's biomedical industry
.
In recent years, with the support of favorable policies, in the context of the continuous growth of the domestic pharmaceutical market and the increasing acceptance of innovative therapies in the country, local innovative companies are constantly developing innovative drugs and are facing a large scale.
, While paying more and more attention to innovation in the domestic market, it is also continuing to expand the international market
.
Therefore, affected by this in the future, more and more innovative companies will attract the attention of strategic investors
.
And this will also inject more momentum into the pharmaceutical and biological market, thereby better promoting the innovation and high-quality development of the pharmaceutical and biological industry
.
